Emilia Scalzulli

Pubblicazioni

Titolo Pubblicato in Anno
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia EUROPEAN JOURNAL OF HAEMATOLOGY 2020
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms AMERICAN JOURNAL OF HEMATOLOGY 2020
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors CLINICAL DRUG INVESTIGATION 2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience ANNALS OF HEMATOLOGY 2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera EXPERT REVIEW OF HEMATOLOGY 2020
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab ANNALS OF HEMATOLOGY 2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients ANNALS OF HEMATOLOGY 2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice EXPERT REVIEW OF HEMATOLOGY 2020
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors ANNALS OF HEMATOLOGY 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy BLOOD CANCER JOURNAL 2020
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previousTKIs AMERICAN JOURNAL OF HEMATOLOGY 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib HEMATOLOGICAL ONCOLOGY 2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience ANNALS OF HEMATOLOGY 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance LEUKEMIA & LYMPHOMA 2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera EXPERT REVIEW OF HEMATOLOGY 2020
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib BLOOD 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance LEUKEMIA & LYMPHOMA 2020
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia THERAPEUTIC ADVANCES IN HEMATOLOGY 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart HEMATOLOGICAL ONCOLOGY 2019

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma